31 research outputs found
Oral Contraceptives and Multiple Sclerosis/Clinically Isolated Syndrome Susceptibility.
BACKGROUND:The incidence of multiple sclerosis (MS) is rising in women. OBJECTIVE:To determine whether the use of combined oral contraceptives (COCs) are associated with MS risk and whether this varies by progestin content. METHODS:We conducted a nested case-control study of females ages 14-48 years with incident MS or clinically isolated syndrome (CIS) 2008-2011 from the membership of Kaiser Permanente Southern California. Controls were matched on age, race/ethnicity and membership characteristics. COC use up to ten years prior to symptom onset was obtained from the complete electronic health record. RESULTS:We identified 400 women with incident MS/CIS and 3904 matched controls. Forty- percent of cases and 32% of controls had used COCs prior to symptom onset. The use of COCs was associated with a slightly increased risk of MS/CIS (adjusted OR = 1.52, 95%CI = 1.21-1.91; p<0.001). This risk did not vary by duration of COC use. The association varied by progestin content being more pronounced for levenorgestrol (adjusted OR = 1.75, 95%CI = 1.29-2.37; p<0.001) than norethindrone (adjusted OR = 1.57, 95%CI = 1.16-2.12; p = 0.003) and absent for the newest progestin, drospirenone (p = 0.95). CONCLUSIONS:Our findings should be interpreted cautiously. While the use of some combination oral contraceptives may contribute to the rising incidence of MS in women, an unmeasured confounder associated with the modern woman's lifestyle is a more likely explanation for this weak association
Improving quality, affordability, and equity of multiple sclerosis care
Abstract Objective The prevailing approaches to selecting multiple sclerosis (MS) disease modifying therapies (DMTs) have contributed to exponential increases in societal expenditures and outāofāpocket expenses, without compelling evidence of improved outcomes. Guidance is lacking regarding when and in whom the benefits of preventing MSārelated disability likely outweighs the risks of highly effective DMTs (HET) and when it is appropriate to consider DMT costs. Our objective was to develop a standardized approach to improve the quality, affordability and equity of MS care. Methods MS experts partnered with health plan pharmacists to develop an ethical, riskāstratified, costāsensitive treatment algorithm. We developed a riskāstratification schema to classify patients with relapsing forms of MS as high, intermediate or low risk of disability based on the best available evidence and, when the evidence was poor or lacking, by consensus. DMTs are grouped as highly, modestly or low/uncertain effectiveness and preferentially ranked within groups by safety based on preāspecified criteria. We reviewed FDA documents and the published literature. When efficacy and safety are equivalent, the lower cost DMT is preferred. Results Assignment to the highārisk group prompts treatment with preferred HETs early in the disease course. For persons in the intermediateā or lowārisk groups with cost or health care access barriers, we incorporated induction therapy with an affordable Bācell depleting agent. Based on more favorable safety profiles, our preferred approach prioritizes use of rituximab and natalizumab among HETs and interferonābetas or glatiramer acetate among modestly effective agents. Interpretation The riskāstratified treatment approach we recommend provides clear, measurable guidance in whom and when to prescribe HETs, when to prioritize lower cost DMTs and how to accommodate persons with MS with cost or other barriers to DMT use. It can be adapted to other cost structures and updated quickly as new information emerges. We recommend that physician groups partner with health insurance plans to adapt our approach to their settings, particularly in the United States. Future studies are needed to resolve the considerable uncertainty about how much variability in prognosis specific risk factors explain
Association between combined oral contraceptives and MS (n = 239 cases/2322 controls).
<p>Association between combined oral contraceptives and MS (n = 239 cases/2322 controls).</p
Baseline demographic and clinical characteristics.
<p>Baseline demographic and clinical characteristics.</p
Association between Progestin Content of COC and MS/CIS.
<p>Association between Progestin Content of COC and MS/CIS.</p
Characteristics of hormonal contraceptive use.
<p>Characteristics of hormonal contraceptive use.</p